Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18519686 
Yan J, Yang XP, Kim YS, Jetten AM (2008) RAP80 responds to DNA damage induced by both ionizing radiation and UV irradiation and is phosphorylated at Ser 205. Cancer Res 68, 4269-76 18519686
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Download Sites

S205-p - RAP80 (human)
Orthologous residues
RAP80 (human): S205‑p, RAP80 (mouse): S205‑p, RAP80 (rat): S205‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  ataxia-telangiectasia, bone cancer, breast cancer, Seckel syndrome
 Relevant cell lines - cell types - tissues:  293T (epithelial), GM05757 (fibroblast), GM05823 (fibroblast), GM18366 (fibroblast), HCC1937 (breast cell), MCF-7 (breast cell), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ATM (human) genetic knockout/knockin of upstream enzyme
KINASE ATR (human) genetic knockout/knockin of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing radiation increase
ionizing radiation BRCA1 (human) no effect upon treatment-induced increase
UV increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.